Scarica l'app Stockscreener
1.13
20.69%
0.1937
Dopo l'orario di chiusura:
1.13
Precedente Chiudi:
$0.9363
Aprire:
$0.95
Volume 24 ore:
5.38M
Relative Volume:
3.15
Capitalizzazione di mercato:
$129.50M
Reddito:
$13.45M
Utile/perdita netta:
$-178.23M
Rapporto P/E:
-0.6848
EPS:
-1.65
Flusso di cassa netto:
$-132.53M
1 W Prestazione:
+8.65%
1M Prestazione:
-1.74%
6M Prestazione:
-11.02%
1 anno Prestazione:
-66.17%
Intervallo 1D:
$0.95
$1.24
Intervallo di 1 settimana:
$0.91
$1.24
Portata 52W:
$0.6611
$4.20
Fate Therapeutics Inc Stock (FATE) Company Profile
Nome
Fate Therapeutics Inc
Settore
Industria
Telefono
858.875.1803
Indirizzo
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Confronta FATE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
FATE
Fate Therapeutics Inc
|
1.13 | 107.33M | 13.45M | -178.23M | -132.53M | -1.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-18 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2024-06-17 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | Ripresa | Wells Fargo | Equal Weight |
| 2023-01-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-01-06 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-06 | Downgrade | BofA Securities | Buy → Underperform |
| 2023-01-06 | Downgrade | Cowen | Outperform → Market Perform |
| 2023-01-06 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2023-01-06 | Downgrade | Stifel | Buy → Hold |
| 2023-01-06 | Downgrade | Truist | Buy → Hold |
| 2023-01-06 | Downgrade | Wedbush | Outperform → Neutral |
| 2023-01-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-12-22 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-12-15 | Iniziato | Goldman | Sell |
| 2022-11-04 | Ripresa | Cantor Fitzgerald | Overweight |
| 2022-10-10 | Iniziato | Canaccord Genuity | Buy |
| 2022-08-18 | Ripresa | Wells Fargo | Overweight |
| 2022-07-28 | Iniziato | Needham | Hold |
| 2022-07-11 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2022-06-03 | Iniziato | Robert W. Baird | Neutral |
| 2022-02-11 | Ripresa | BMO Capital Markets | Market Perform |
| 2021-12-15 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2021-12-07 | Iniziato | Cowen | Outperform |
| 2021-11-09 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-08-26 | Iniziato | Morgan Stanley | Equal-Weight |
| 2021-06-07 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2021-05-07 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2021-04-26 | Ripresa | Jefferies | Buy |
| 2021-02-26 | Iniziato | BofA Securities | Buy |
| 2021-02-26 | Downgrade | Wedbush | Outperform → Neutral |
| 2021-02-11 | Downgrade | Citigroup | Buy → Neutral |
| 2021-01-27 | Ripresa | H.C. Wainwright | Neutral |
| 2020-05-13 | Iniziato | H.C. Wainwright | Buy |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-01-09 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2019-12-30 | Reiterato | Mizuho | Buy |
| 2019-12-09 | Aggiornamento | Wells Fargo | Market Perform → Outperform |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-11-06 | Downgrade | Wells Fargo | Outperform → Market Perform |
| 2019-10-01 | Iniziato | Stifel | Buy |
| 2019-08-09 | Iniziato | BTIG Research | Buy |
| 2019-07-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-07-12 | Iniziato | Oppenheimer | Outperform |
| 2019-06-13 | Iniziato | Mizuho | Buy |
| 2019-06-07 | Iniziato | ROTH Capital | Neutral |
| 2019-05-31 | Iniziato | Guggenheim | Buy |
| 2019-05-24 | Ripresa | Citigroup | Buy |
| 2019-03-28 | Iniziato | SVB Leerink | Outperform |
| 2019-01-03 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2018-11-05 | Iniziato | Jefferies | Buy |
| 2018-08-01 | Iniziato | Citigroup | Buy |
| 2018-03-06 | Downgrade | H.C. Wainwright | Buy → Neutral |
Mostra tutto
Fate Therapeutics Inc Borsa (FATE) Ultime notizie
Fate Therapeutics Announces Corporate Restructuring Plan - MSN
Wells Fargo lowers Fate Therapeutics stock price target to $2.50 on cost cuts - Investing.com Canada
Fate Therapeutics 2025 Q2 Earnings Narrowed Losses but Revenue Falls Sharply - AInvest
Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates - GlobeNewswire
Bullish Divergence Spotted in Fate Therapeutics Inc. MomentumAccurate Buy Point for Momentum Stocks Detected - 선데이타임즈
Fate Therapeutics earnings beat by $0.05, revenue topped estimates - Investing.com Canada
Fate Therapeutics: Q2 Earnings Snapshot - San Francisco Chronicle
Fate Therapeutics (FATE) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Fate Therapeutics' Q2 2025 Earnings: A Strategic Catalyst for Long-Term Shareholder Value - AInvest
Fate Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Can machine learning forecast Fate Therapeutics Inc. recoveryBuy Opportunity Forecast for Fast Traders - Newser
What makes Fate Therapeutics Inc. stock price move sharplyHigh Conviction Stock Long-Term Summary - Newser
Why Fate Therapeutics Inc. stock attracts strong analyst attentionFree Real Time Trade Opportunity Alerts - Newser
Analyzing net buyer seller activity in Fate Therapeutics Inc.Free Entry and Exit Strategy Optimizer Tool - Newser
Fate Therapeutics Inc. stock trend forecastFree Risk Controlled Picks With Real Returns - Newser
Fate Therapeutics Inc expected to post a loss of 34 cents a shareEarnings Preview - TradingView
Trapped Investors in Fate Therapeutics Inc. Await Breakout SignalWatchlist for Smart Swing Trading Updated - metal.it
Fate Therapeutics shares fall 4.52% intraday due to unspecified reasons. - AInvest
Full technical analysis of Fate Therapeutics Inc. stockSwing Trade Picks with High Potential - Newser
Fate Therapeutics shares fall 4.17% intraday after granting non-qualified stock options to a new employee. - AInvest
Fate Therapeutics CEO Makes a Notable Stock Sale! - TipRanks
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Fate Therapeutics' Strategic Talent Acquisition and Equity Incentive Program: A Catalyst for Biotech Innovation and Shareholder Value - AInvest
Fate Therapeutics reports new employee inducement awards - MarketScreener
Fate Therapeutics CEO Valamehr sells $15,396 in stock By Investing.com - Investing.com Nigeria
Fate Therapeutics CEO Valamehr sells $15,396 in stock - Investing.com
Cwm LLC Buys 37,290 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Fate Therapeutics (NASDAQ:FATE) Upgraded at Wall Street Zen - Defense World
Fate Therapeutics Inc. Nearing Breakout Level After BounceAccurate Technical Trend Reversal Picks Detected - metal.it
What catalysts could drive Fate Therapeutics Inc. stock higher in 2025Capitalize on trading strategies that deliver - Jammu Links News
What is the dividend policy of Fate Therapeutics Inc. stockFree Stock Market Return Analysis - Jammu Links News
How strong is Fate Therapeutics Inc. company’s balance sheetFree Capital Efficiency Planning - Jammu Links News
How does Fate Therapeutics Inc. generate profit in a changing economyFree Stock Market Trend Analysis - Jammu Links News
Wells Fargo Maintains Fate Therapeutics(FATE.US) With Hold Rating, Maintains Target Price $4 - 富途牛牛
What is Fate Therapeutics Inc. company’s growth strategyUnlock exclusive stock market insights - Jammu Links News
What are Fate Therapeutics Inc. company’s key revenue driversUnlock powerful trading signals and alerts - Jammu Links News
How does Fate Therapeutics Inc. compare to its industry peersBuild a diversified portfolio for risk mitigation - Jammu Links News
Does Fate Therapeutics Inc. stock perform well during market downturnsMassive stock growth - Jammu Links News
Is Fate Therapeutics Inc. a growth stock or a value stockInvest confidently with market-leading analysis - Jammu Links News
Fate Therapeutics’ Phase 1 Study: A New Hope for Autoimmune Diseases - TipRanks
How volatile is Fate Therapeutics Inc. stock compared to the marketTop Growth Tracker With Low Risk - Jammu Links News
Published on: 2025-07-30 19:50:13 - metal.it
Published on: 2025-07-30 17:10:31 - beatles.ru
Published on: 2025-07-30 08:12:45 - metal.it
How Resilient Is Fate Therapeutics Inc. Stock During Economic DownturnsDaily Smart Money Movement Monitor Activated - metal.it
Fate Therapeutics Inc Azioni (FATE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.67%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):